STATUS: Research Stage | CNS-Penetrant Oral Inflammasome Inhibition [CALL OUT BOX]
Amyotrophic lateral sclerosis is a rare and devastating neurodegeneration of the upper motor neurons in the motor cortex and the lower motor neurons in the brainstem and spinal cord. Patients experience progressive weakness of limb, respiratory, and bulbar muscles, and mortality due to respiratory failure is common within 2 to 3 years of symptom onset. Currently approved treatments, Rilutek, Radicava, Relyviro, and QALSODY, have modest effects on disease modification and survival, leaving a large unmet need. Several misfolded proteins implicated in ALS pathogenesis, including TDP-43, SOD1G93A, Pr50, and poly GA aggregates, induce inflammasome activation. NLRP3, NLRC4, IL-18, IFN-gamma, and Caspase-1 are increased in post-mortem tissue and circulation of ALS patients, supporting the concept that inflammasome inhibition could be beneficial. In November 2025, Inflammasome Therapeutics announced a collaboration with the Sean M. Healey and AMG Center for ALS to develop a new treatment for the disease.
K9 vs. QALSODY: Neurofilament Light Chain Reduction
Kamuvudine-9 inhibits inflammasome activation and the Th1/Th17 lymphocyte axes in multiple animal models. In an animal model of neurodegeneration:
- K9 reduced serum neurofilament light chain (NfL) by 98%
- QALSODY (tofersen), the most recently FDA-approved ALS therapy, reduces plasma NfL by approximately 50%
QALSODY received accelerated FDA approval on the basis of its NfL reduction. K9's 98% reduction in the same biomarker compares favorably.
[Call out Box]